Xeris Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 11, 2020
February 27, 2020 16:05 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and...
Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock
February 11, 2020 19:06 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces Proposed Public Offering of 6,000,000 Shares of Common Stock
February 10, 2020 16:06 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 27, 2019 16:05 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Dec. 27, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 29, 2019 13:05 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Provides a Business Update During Recent Investor Conference
November 21, 2019 06:00 ET
|
Xeris Pharmaceuticals, Inc.
MAA submitted to EMA of liquid stable glucagon for severe hypoglycemiaGVOKE™ PFS launch underwayGVOKE HypoPen™ expected to launch July 2020CHI program shifts to Expanded AccessHAAF program...
Xeris Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights
November 07, 2019 08:00 ET
|
Xeris Pharmaceuticals, Inc.
Gvoke™ (glucagon injection) pre-filled syringe (PFS) - now available by prescription MAA for ready-to-use glucagon on track for submission to EMA by year-end Data from three Phase 2 studies expected...
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 01, 2019 16:05 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Appoints Mark Thierer to Board of Directors
October 01, 2019 08:00 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and...
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
September 27, 2019 16:05 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...